Tanvex BioPharma, Inc. (6541.TW)
TWD 63.5
(1.11%)
TWD 63.5
(1.11%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 61.41 Million | 22.4 Million | 5.4 Million | 300 Thousand | - | - |
| Cost of Revenue | 1.71 Million | 41.75 Million | 1.85 Million | 157 Thousand | 215.96 Million | 142.76 Million |
| Gross Profit | 59.7 Million | -19.34 Million | 3.55 Million | 143 Thousand | -215.96 Million | -142.76 Million |
| Operating Expenses | 2.16 Billion | 1.58 Billion | 1.6 Billion | 2.09 Billion | 2.32 Billion | 1.95 Billion |
| Selling, General and Administrative Expenses | 453.7 Million | 234.74 Million | 219.21 Million | 239.12 Million | 328.04 Million | 297.74 Million |
| Research and Development Expenses | 1.7 Billion | 1.35 Billion | 1.38 Billion | 1.86 Billion | 2 Billion | 1.65 Billion |
| Other Expenses | - | 9.53 Million | 99.07 Million | -4.72 Million | 69.53 Million | 56.74 Million |
| Cost and Expenses | 2.16 Billion | 1.62 Billion | 1.6 Billion | 2.09 Billion | 2.32 Billion | 1.95 Billion |
| Operating Income | -2.1 Billion | -1.58 Billion | -1.49 Billion | -2.08 Billion | -2.25 Billion | -1.95 Billion |
| Interest Expense | 57.38 Million | 54.72 Million | 46.22 Million | 18.57 Million | 15.58 Million | - |
| Income Tax Expense | 428 Thousand | 23 Thousand | 22 Thousand | 24 Thousand | 25 Thousand | 24 Thousand |
| Earnings before Tax | -2.13 Billion | -1.64 Billion | -1.54 Billion | -2.1 Billion | -2.27 Billion | -1.89 Billion |
| Net Income | -2.13 Billion | -1.64 Billion | -1.54 Billion | -2.1 Billion | -2.27 Billion | -1.89 Billion |
| Earnings Per Share Basic | -16.42 | -13.55 | -13.80 | -22.61 | -26.16 | -24.94 |
| Earnings Per Share Diluted | -16.42 | -13.55 | -13.80 | -22.61 | -26.16 | -23.72 |
| Weighted Average Shares Outstanding | 130.12 Million | 121.14 Million | 111.84 Million | 93.05 Million | 86.93 Million | 75.93 Million |
| Weighted Average Shares Outstanding (Diluted) | 130.12 Million | 121.14 Million | 111.84 Million | 93.05 Million | 86.93 Million | 79.82 Million |
| Gross Margin | 0.97 | -0.86 | 0.66 | 0.48 | - | - |
| EBIT Margin | -28.57 | -58.24 | -231.85 | -6217.45 | - | - |
| Profit Margin | -34.80 | -73.25 | -285.46 | -7014.12 | - | - |
| EBITDA | -1.75 Billion | -1.3 Billion | -1.25 Billion | -1.86 Billion | -2.04 Billion | -1.75 Billion |
| Earnings Before Tax Margin | -34.21 | -70.81 | -276.91 | -6952.14 | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 17 Million | 3.35 Million | 61.41 Million | 9.08 Million | 5.1 Million | 17.08 Million |
| Cost of Revenue | 89.49 Million | 75.08 Million | 326.54 Million | 88.97 Million | 990 Thousand | 6.03 Million |
| Gross Profit | -72.49 Million | -71.72 Million | -265.13 Million | -79.89 Million | 4.11 Million | 11.04 Million |
| Operating Expenses | 290.47 Million | 350.29 Million | 1.83 Billion | 412.73 Million | 511.46 Million | 512.12 Million |
| Selling, General and Administrative Expenses | 85.59 Million | 58.81 Million | - | 124.82 Million | 97.1 Million | 103.76 Million |
| Research and Development Expenses | 204.87 Million | 291.47 Million | - | 287.91 Million | 414.35 Million | 408.35 Million |
| Other Expenses | 1.71 Million | 13.23 Million | -7.57 Million | -16.25 Million | 8.07 Million | 3000.00 |
| Cost and Expenses | 379.97 Million | 425.37 Million | 2.16 Billion | 501.71 Million | 512.45 Million | 518.15 Million |
| Operating Income | -362.96 Million | -422.01 Million | -2.1 Billion | -492.63 Million | -491.2 Million | -491.56 Million |
| Interest Expense | 14.06 Million | 14.39 Million | 57.38 Million | 16.69 Million | 13.73 Million | 13.93 Million |
| Income Tax Expense | 318 Thousand | 72.34 Million | 428 Thousand | -23 Thousand | 402 Thousand | 49 Thousand |
| Earnings before Tax | -366.4 Million | -418.16 Million | -2.13 Billion | -518.03 Million | -504.94 Million | -505.49 Million |
| Net Income | -366.72 Million | -418.16 Million | -2.13 Billion | -518.01 Million | -505.34 Million | -505.54 Million |
| Earnings Per Share Basic | -2.31 | -3.12 | - | -3.83 | -3.74 | -3.85 |
| Earnings Per Share Diluted | -2.31 | -3.12 | - | -3.83 | -3.74 | -3.85 |
| Weighted Average Shares Outstanding | 158.69 Million | 133.98 Million | 130.12 Million | 135.24 Million | 134.96 Million | 131.35 Million |
| Weighted Average Shares Outstanding (Diluted) | 158.69 Million | 133.98 Million | 130.12 Million | 135.24 Million | 134.96 Million | 131.35 Million |
| Gross Margin | -4.26 | -21.37 | -4.32 | -8.79 | 0.81 | 0.65 |
| EBIT Margin | -17.10 | -104.15 | - | -44.98 | -80.24 | -23.99 |
| Profit Margin | -21.56 | -124.56 | -34.80 | -57.01 | -98.99 | -29.60 |
| EBITDA | -290.9 Million | -349.62 Million | - | -408.73 Million | -409.64 Million | -409.72 Million |
| Earnings Before Tax Margin | -21.34 | -125.71 | -34.21 | -54.21 | -96.22 | -28.78 |
YALA
5203
SKBSY
BFS-PD
NVRO
002549